VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
07/19/2022 - 08:00 AM
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022.
B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) – Presentation Details Presentation Date: July 27, 2022 Presenter: Iain Stuart, Ph.D., Chief Scientific Officer of VYNE Presentation Track: Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated Autoimmune Disease Landscape Presentation Title: The InhiBET™ Platform: Bromodomain and End Terminal (BET) Inhibitors in Autoimmune Disease
Slides will be accessible on the “Events and Presentation” section of the VYNE website at https://vynetherapeutics.com/investors-media/events_presentations/
About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis, and access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com . VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations: John Fraunces LifeSci Advisors, LLC 917-355-2395jfraunces@lifesciadvisors.com
Tyler Zeronda VYNE Therapeutics Inc. 908-458-9106Tyler.Zeronda@VYNEtx.com
VYNE Rankings
N/A Ranked by Stock Gains
VYNE Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About VYNE
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.